Amneal, through subsidiary Amneal Pharmaceuticals LLC, acquired a 98% interest in the unit of Kashiv BioSciences LLC for approximately $100 million.
“We are very pleased to announce the completion of this transaction,” Chirag and Chintu Patel, co-CEOs of Amneal, said in a prepared statement. “Through the acquisition of Kashiv Specialty Pharma, Amneal has gained an exciting pipeline of both 505(b)2 branded products and complex generics. Perhaps most importantly, we are adding a team of world-class R&D scientists with a proven track record of developing complex generic products, as well as a platform of innovative drug delivery technologies.”
The deal was first announced in January.